Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down – Here’s Why

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s share price gapped down prior to trading on Wednesday. The stock had previously closed at $17.92, but opened at $17.26. Daiichi Sankyo shares last traded at $18.1650, with a volume of 3,337 shares.

Analyst Ratings Changes

DSNKY has been the topic of several analyst reports. Jefferies Financial Group cut Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Zacks Research upgraded Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Monday, September 21st. Two research analysts have rated the stock with a Hold rating. Based on data from MarketBeat, Daiichi Sankyo has a consensus rating of “Hold”.

Daiichi Sankyo Stock Performance

The stock has a market cap of $33.74 billion, a PE ratio of 21.06, a price-to-earnings-growth ratio of 1.85 and a beta of -0.11. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92. The company’s 50 day simple moving average is $17.79 and its 200 day simple moving average is $17.16.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings results on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The business had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. Analysts expect that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.93 earnings per share for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.